

Journal Pre-proof

Low-Dose Oral Minoxidil as Treatment for COVID-19–Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients

CD Villarreal-Villarreal MD E Boland-Rodriguez D Mares-Custodio
MD Daniel Asz-Sigall JF Molina-de la Garza MD D Saceda-Corrado
MD PhD S Vano-Galvan MD PhD



PII: S0001-7310(25)00845-2

DOI: <https://doi.org/doi:10.1016/j.ad.2025.104569>

Reference: AD 104569

To appear in: *Actas dermosifiliograficas*

Received Date: 22 October 2024

Accepted Date: 20 February 2025

Please cite this article as: Villarreal-Villarreal C, Boland-Rodriguez E, Mares-Custodio D, Asz-Sigall D, Molina-de la Garza J, Saceda-Corrado D, Vano-Galvan S, Low-Dose Oral Minoxidil as Treatment for COVID-19–Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients, *Actas dermosifiliograficas* (2025), doi: <https://doi.org/10.1016/j.ad.2025.104569>

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: <https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article>. Please also note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 Published by Elsevier España, S.L.U. on behalf of AEDV.

Sección. Original article

Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients

Authors: CD Villarreal-Villarreal MD^{a,b,h}, E Boland-Rodriguez^{a,i}, D Mares-Custodio MD^{b,j}, Daniel Asz-Sigall^{g,n}, Molina-de la Garza JF MD^{a,k}, D Saceda-Corralo MD, PhD^{c,d,e,l}, and S Vano-Galvan MD, PhD^{c,d,f,m}

- a) CEDAVI Derma experts, Hair Restoration Unit. Monterrey, Mexico.
- b) Tecnológico de Monterrey - Escuela de Medicina y Ciencias de la Salud. Monterrey, Mexico.
- c) Servicio de Dermatología. Hospital Universitario Ramón y Cajal, IRYCIS. Madrid, Spain.
- d) Trichology Unit, Grupo de Dermatología Pedro Jaén. Madrid, Spain.
- e) Departamento de Biología de Sistemas, Facultad de Medicina, Universidad de Alcalá, IRYCIS. Madrid, Spain.
- f) Departamento de Medicina, Facultad de Medicina, Universidad de Alcalá, IRYCIS. Madrid, Spain.
- g) Trichology clinic, Dermatology Department. Hospital General Manuel Gea Gonzalez, México.

Corresponding author: César Daniel Villarreal-Villarreal.

E-mail address: dr.cesarvillarrealderma@gmail.com

ABSTRACT

Background and objective: Coronavirus disease 2019 (COVID-19) associated telogen effluvium (CATE) has been observed in patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although it is self-limiting, hair loss can be very distressing, and some patients may seek medical treatment to help promote hair regrowth. Low-dose oral minoxidil (LDM) has emerged as a novel and very efficient therapy for different types of alopecia. However, information on its safety and efficacy profile in the management of CATE remains scarce. This study aims to evaluate the treatment response to LDM in CATE patients.

Methods: We conducted a retrospective study at a single dermatology center. Adult patients diagnosed with telogen effluvium from December 2020 through October 2022, with a prior history of SARS-CoV-2 infection, and treated with LDM were included. The efficacy of LDM was evaluated with the hair-shedding score (HSS).

Results: In all, 69 patients, 50 (72.5%) women and 19 (27.5%) men were included. A total of 55 patients (79.7%) exhibited mild and moderate symptoms; 8 (11.5%), severe disease; and 6 (8.7%) remained asymptomatic. The time elapsed between COVID-19 and telogen effluvium diagnosis was 117 days (80-181). The HSS continuously decreased during the 2nd, 3rd, and 4th visits after treatment initiation. Compared with baseline, the median (interquartile range) HSS was significantly lower at the 2nd visit (5 [5-6]; $P < .001$), the 3rd visit (4 [3-5]; $P < .001$), and the 4th visit (2 [1-2]; $P < .001$). The time for telogen effluvium resolution was 93 days (55-148).

Conclusions: Our findings suggest that LDOM is a safe and effective therapy for patients with CATE.

Keywords: Androgenetic alopecia, minoxidil, hair loss, hair shedding, COVID-19, telogen effluvium.

ABBREVIATIONS

CATE: COVID-19 associated telogen effluvium.

COVID-19: Coronavirus disease 2019.

FPHL: female patterned hair loss.

HSS: Hair-shedding score.

LDOM: Low-dose oral minoxidil.

MAGA: male androgenetic alopecia.

PCR: polymerase chain reaction.

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

TE: telogen effluvium.

INTRODUCTION

The Coronavirus disease 2019 (COVID-19) pandemic is an ongoing global health crisis caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Observational studies have found an association between new-onset telogen effluvium (TE) and patients infected with COVID-19 (1).

TE is a cause of non-scarring alopecia due to the disruption of the hair growth cycle. Diffuse excessive telogen hair loss usually occurs about 2-3 months after a triggering event, such as illness, surgery, or childbirth. Based on remission time, it can be categorized as acute or chronic TE. The former typically resolves within 6 months, while persistent hair shedding lasting longer than 6 months is called chronic TE (2).

COVID-19 infection is a frequent cause of acute TE. This association is primarily related to the systemic hyperinflammatory syndrome or cytokine storm triggered by the virus. The cytokine storm is an impaired acquired immune response and uncontrolled inflammatory innate response based on the activation of Th1 cells with the subsequent secretion of proinflammatory cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6). GM-CSF further activates CD14⁺CD16⁺ inflammatory monocytes that produce more IL-6, tumor necrosis factor- α (TNF- α), IL-1 β , IL-8, and IL-12 (3,4). Furthermore, the increased psychosocial and physiological stress caused by COVID-19 has been involved in its pathophysiology (5). In those cases, the disease is considered COVID-19 associated telogen effluvium (CATE) (6).

SARS-CoV-2 infection induces a proinflammatory state with elevated levels of circulating cytokines such as IL-1 β , IL-6, and interferon- γ (IFN- γ), cytokines implicated in the hair growth cycle (7,8). IL-6 is involved in severe forms of viral infection and related TE. It predisposes and exacerbates hair loss by inhibiting the first phase of the hair growth cycle (anagen phase) and hair follicle proliferation (9). In addition, IL-1 β and IFN- γ are implicated in the intermediate phase of the hair growth cycle (catagen phase) (9).

TE is typically characterized by temporary hair loss, which eventually will grow back unless associated with other underlying medical conditions. Although it is self-limiting, hair loss can be very distressing, and some patients may seek medical treatment to help promote hair regrowth (10).

Low-dose oral minoxidil (LDM) is a vasodilator drug that has shown promising results in treating hair loss. Its mechanism of action is unknown; however, it is thought to stimulate hair growth by boosting blood supply to hair follicles and promoting growth factors (11). Despite insufficient data on the efficacy of CATE, studies have shown that it helps treat other types of hair loss (12). Because the prevalence of hair loss has increased following COVID-19 infection, it is critical to examine potential therapies.

This study aims to evaluate the treatment response to LDM in patients with CATE through changes in the hair-shedding score (HSS).

MATERIALS AND METHODS

We conducted a retrospective study with patients treated from December 2020 through October 2022 at a single dermatology center in San Pedro Garza Garcia, Mexico. Inclusion criteria were ≥ 18 years, a past medical history of SARS-Cov-2 infection confirmed by polymerase chain reaction (PCR), and no history of TE before COVID-19 infection. Health records were accessed through the "Compu-expedient" electronic platform with authorization from CEDAVI-Derma experts.

No exclusion criteria were applied for concomitant forms of alopecia. The diagnosis of telogen effluvium was established based on clinical features, physical examination, and a positive hair pull test, supported by trichoscopy, which demonstrated telogen hairs and the absence of anisotrichosis (DermLite DL4). Clinical and demographic data were extracted from the health records of eligible patients. The date of the patient's vaccination status, symptoms, and severity of COVID-19 were considered as well. Severe infection was defined by the presence of pneumonia, dyspnea, or hospitalization.

On the first visit, iconographies were taken, a baseline HSS was established, and vital signs were documented. Subsequent follow-up appointments involved recording the patient's vital signs and subjective response to treatment based on the HSS. Patients were followed from the date of CATE diagnosis until the last visit or resolution when the final HSS was noted. A resolution was marked by the absence of hair shedding or hair regrowth.

Hamilton and Sinclair's scales were calculated, if applicable (13). Furthermore, adverse events and dosage were recorded from medical records. Minoxidil doses ranged from 1 mg to 5 mg based on the patient's tolerance starting with the lower dose.

COVID-19 variants were inferred based on the date of diagnosis and epidemiological week reports issued by the national health authority (14).

All procedures were conducted in full compliance with the ethical standards outlined by the institutional ethics committee on human experimentation and in full compliance with the Declaration of Helsinki.

Statistical analysis

Continuous variables were expressed as mean \pm standard deviation (SD) or median (interquartile range, IQR) depending on whether they had a normal distribution. Ordinal variables were expressed as median (IQR). Categorical variables were recorded as frequency

(percentage). Continuous variables with normal distribution between baseline and follow-ups were compared using paired t-tests. The comparison of continuous variables in abnormal distribution and ordinal variables between baseline and follow-ups was analyzed using the Wilcoxon rank-sum test. Quantitative data were analyzed using the chi-square test. P-values < 0.05 were considered statistically significant. The SPSS 24.0 software (SPSS Inc., Chicago, IL, United States) was used for the statistical analysis.

RESULTS

Baseline characteristics

A total of 69 patients with a diagnosis of TE and a prior diagnosis of SARS-CoV-2 infection were included. Fifty (72.5%) patients were women and 19 (27.5%) were men. Their ages ranged from 21 to 70 years with a mean and SD of 38.1 ± 11.7 . A total of 55 (79.7%) patients exhibited mild and moderate symptoms; 8 (11.5%) exhibited severe disease; and 6 (8.7%) remained asymptomatic. A total of 52 (75.4%) patients received, at least, 1 COVID-19 vaccine, and only 22 (31.9%) received a booster. A total of 35 (50.7%) had a previous diagnosis of female patterned hair loss (FPHL), 17 (24.6%) had male androgenetic alopecia (MAGA), 1 (1.4%) had lichen planopilaris, while 16 (23.2%) did not exhibit any type of alopecia (Table 1). All patients received daily oral minoxidil; 53 (76.8%) patients were on a dosage of 1 mg, 14 (20.3%) on a dosage of 2.5 mg, and 2 (2.9%) on a dosage of 5 mg. A total of 21 (31.3%) patients reported adverse effects, including hypertrichosis 17 (24.6%) and edema of the limbs 4 (5.8%). The median interval between COVID-19 diagnosis and the onset of telogen effluvium was 117 days, and the median time from telogen effluvium diagnosis to cessation of hair shedding was 93 days (55–148) (Table 2). The most frequent probable variant in our cohort was the initial Omicron variant (34 patients [49.3%]), followed by the first wave strain (18 [26.1%]), Delta (13 [18.8%]), and Alpha (4 [5.8%]). When comparing the HSS among variants during the visits, we found no statistical difference among them.

Hair-shedding score

The HSS continuously decreased during the 2nd, 3rd, and 4th visits following treatment initiation (Figure 1). Compared with baseline, the median (interquartile range) Hair Shedding Score decreased to 5 (5-6) at the 2nd visit ($P < .001$), 4 (3-5) at the 3rd visit ($P < .001$), and 2 (1-2) at the 4th visit ($P < .001$) (Table 3). The time elapsed between COVID-19 and TE diagnosis was 117 days (80-181); between TE diagnosis and the 2nd visit, 38 days (33–54); and between the 2nd visit and the last visit when the TE stopped, 93 days (55–148).

Hair-shedding score in FPHL and MAGA

When changes in the HHS were compared between FPHL and MAGA visits, no statistically significant difference was observed between baseline and the 2nd visit (FPHL: 2 [1-2] vs MAGA: 1 [0-2]; $P = .095$). In contrast, statistically significant differences were identified at the 3rd visit ($P < .004$) and at the 4th visit ($P < .004$) (Table 4).

Hypertrichosis

Patients who developed hypertrichosis had a duration of treatment with minoxidil longer than those who did not, 396 (292-580) vs 259 (204-363), respectively ($p = 0.04$). When the incidence of hypertrichosis after low-dose oral minoxidil treatment was compared between patients with preexisting hair disorders, those with FPHL showed a higher incidence rate (40%) than those with MAGA (11.8%) (Table 5).

DISCUSSION

The COVID-19 pandemic affected millions of people worldwide, causing a wide range of symptoms. In addition to the well-known respiratory symptoms and complications associated with SARS-CoV-2 infection, CATE develops in as many as 60% of infected patients (15). In our study, we had a predominance of women (72.5%), similar to what has been found in previous case series (around 80%) (1). However, this has been attributed to probable different causes, one being the disparity between the immune response of both sexes, more susceptibility due to hormonal changes, being women more likely to notice hair thinning and, therefore, more likely to seek treatment (1).

LDOM is the most recent breakthrough treatment and the new trend in treating different types of alopecia. LDOM acts dose-dependent to increase anagen duration, reduce telogen duration, increase fiber diameter, and enlarge miniaturized follicles (16). Furthermore, it has been described that increasing the dose of oral minoxidil by 1 mg on average is associated with a change of 1.30 μm of hair diameter, an increase in total hair density by 47.10 hairs/ cm^2 , and a change in terminal hair density of 9.1 hairs/ cm^2 after 6 months of continuous therapy (17). These mechanisms of action result in decreasing shedding period and increase the hair diameter patients notice good results in CATE.

Recent studies outline a potential pathogenic link between ischemia and disruptions in the hair cycle. The involvement of the respiratory tract and subsequent hypoxemia could induce skin ischemia, diminishing the supply of growth factors to hair follicles (18). In addition, the viral prothrombotic properties may result in microthrombi formation and blood supply blockage (19). In a literature review conducted by Pietro on the correlation between hair loss and TE in patients with COVID-19, it was suggested that protecting cells from ischemia and promoting angiogenesis may serve as a potential treatment for COVID-19-induced hair loss (18). Based on this pathogenic pathway, the effect of minoxidil on blood perfusion may justify HSS improvement in our patients.

There are reports of topical minoxidil 2% in women and 5% in men for CATE treatment (4). However, to our knowledge, this is the first study that investigated the use of LDOM in patients with CATE. Previous research mentioned the usual beginning period for hair loss after COVID-19 diagnosis as 1-6 months (20). In our study, the median start of TE was 117 days (around 4 months) after the COVID-19 diagnosis, which was consistent with the literature. When we categorized the patients by chronicity, we found that acute TE was present in 79.7% of patients with COVID-19, and only 20.3% had chronic TE.

It has been reported that most patients with CATE suffered from a severe infection; however, this is inconsistent with our study since we found that most patients had mild and moderate

infections, probably due to high vaccination among participants (75%) (20). A bigger sample should be considered to accurately discern the correlation between the severity of COVID-19 and the degree of hair loss.

We did not find any statistical difference across COVID-19 variants. Vaccination *per se* could be a trigger for TE; new studies observed a higher incidence rate of alopecia following COVID-19 vaccination (15). Interestingly, more than 3/4 of the patients received at least 1 COVID-19 vaccine, while only about 1/3 received a booster.

In our study, 53 (76.8%) patients were on a dosage of 1 mg, 14 (20.3%) on a dose of 2.5 mg, and 2 (2.9%) on a dose of 5 mg. A total of 21 (31.3%) patients reported adverse effects (21). Notably, most of our patients were women (72.5%), and the most reported dose in this set of patients was 1 mg daily. The dose was mainly influenced by patient's tolerance, with greater doses in the male population vs women.

Response to LDOM was evaluated in the base of HSS. Our results showed a significant reduction in HSS. Compared with baseline, the median HSS was significantly lower at the 2nd visit ($p < 0.001$), 3rd visit ($p < 0.001$), and 4th visit ($p < 0.001$), indicating a sustained medical response. In one study, 36 women with chronic telogen effluvium were treated with oral minoxidil 1 mg daily, resulting in mean reductions in the HSS of 1.7 at 6 months and 2.58 at 12 months vs baseline (22). In our study, the time elapsed between COVID-19 and TE diagnosis was 117 days (80-181); between the TE diagnosis and the 2nd visit, 38 days (33 – 54); and between the 2nd visit and the last visit, when the TE stopped, 93 days (55 – 148). Compared with patients who are not on LDOM, the hair loss is stopped earlier than expected, as acute TE typically resolves within 6 months (2).

Interestingly, about half of the patients had a previous diagnosis of FPHL or MAGA. When comparing the change in HSS between FPHL and MAGA, we found no significant difference in the change of HSS at baseline and 2nd visits between them. However, we found a significant difference in the change of HSS between FPHL and MAGA at the 3rd visit ($p < 0.004$) and the 4th visit ($p < 0.004$), suggesting that the response to LDOM may differ between these two males and women or have a better response with the addition of the underlying comorbid. The consideration of concurrent causes of hair loss, such as MAGA and FPHL, is noteworthy as they might explain the effectiveness of OM beyond the scope of TE alone.

Notably, approximately half of the patients had a prior diagnosis of FPHL or MAGA. When changes in HSS were compared between these groups, no significant differences were observed at baseline or at the 2nd visit. However, significant differences emerged at the 3rd and 4th visits (both $p < 0.004$), suggesting a differential response to low-dose oral minoxidil between FPHL and MAGA. These findings indicate that the presence of concomitant hair

disorders may influence treatment response and could partially explain the effectiveness of oral minoxidil beyond telogen effluvium alone.

Patients should be counseled on the possibility of transient increased shedding, advised not to discontinue therapy, and informed of the need for continuous low-dose oral minoxidil use to maintain therapeutic benefit. Overall, treatment was well tolerated, with only mild adverse effects reported. The most common adverse effect was hypertrichosis (24.6%), followed by peripheral edema (5.8%). These findings are consistent with former reports, in which hypertrichosis is the most frequently reported and appears to be dose dependent. Less common adverse effects included tachycardia and hypotension. No adverse event required treatment discontinuation.

Limitations of our study include the study design because a controlled clinical trial was not conducted, the small sample size, the lack of a control group, the lack of data collection regarding comorbidities and COVID-19 treatment, and the lack of a genotyping test to specify the COVID-19 variant, further studies should be performed to confirm efficacy. The time elapsed between visits varied depending on patients' availability which may have introduced measurement variability. Further prospective studies with larger sample sizes and closer monitoring of participants are needed to confirm our results.

CONCLUSIONS

This retrospective study aimed to evaluate the response to LDOM in adult patients with CATE; our findings suggest that daily LDOM is a safe and effective therapy due to a significant reduction in HSS from baseline in our patient cohort, less shedding, and low adverse effects. While more extensive prospective studies are necessary to determine treatment efficacy conclusively, our findings provide preliminary evidence supporting the use of LDOM in CATE.

Declarations: All authors declared no conflicts of interest whatsoever.

REFERENCES

1. Nguyen B, Tosti A. Alopecia in patients with COVID-19: A systematic review and meta-analysis. *JAAD Int.* 2022;7:67-77. <https://doi.org/10.1016/j.jdin.2022.02.006>.
2. Chien Yin GO, Siong-See JL, Wang ECE. Telogen Effluvium - a review of the science and current obstacles. *J Dermatol Sci.* 2021;101(3):156-63. <https://doi.org/10.1016/j.jdermsci.2021.01.007>.
3. Sattur SS, Sattur IS. COVID-19 Infection: Impact on Hair. *Indian J Plast Surg.* 2021;54(04):521-526. <https://doi.org/10.1055/s-0041-1740289>.
4. Iancu GM, Molnar E, Ungureanu L, Şenilă SC, Haşegan A, Rotaru M. SARS-CoV-2 Infection-A Trigger Factor for Telogen Effluvium: Review of the Literature with a Case-Based Guidance for Clinical Evaluation. *Life.* 2023;13(7):1576. <https://doi.org/10.3390/life13071576>.
5. Di Landro A, Naldi L, Glaser E, Paus R, Tosti A. Pathobiology questions raised by telogen effluvium and trichodynia in COVID-19 patients. *Exp Dermatol.* 2021;30(7):999-1000. <https://doi.org/10.1111/exd.14352>.

6. Aksoy H, Yıldırım UM, Ergen P, Gürel MS. COVID-19 induced telogen effluvium. *Dermatol Ther*. 2021;34(6):e15175. <https://doi.org/10.1111/dth.15175>.
7. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *J Infect*. 2020;80(6):607-13. <https://doi.org/10.1016/j.jinf.2020.03.037>.
8. Ito T, Ito N, Saathoff M, Bettermann A, Takigawa M, Paus R. Interferon-gamma is a potent inducer of catagen-like changes in cultured human anagen hair follicles. *Br J Dermatol*. 2005;152(4):623-31. <https://doi.org/10.1111/j.1365-2133.2005.06453.x>.
9. Gentile P. Hair Loss and Telogen Effluvium Related to COVID-19: The Potential Implication of Adipose-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma as Regenerative Strategies. *Int J Mol Sci*. 2022;23(16):9116. <https://doi.org/10.3390/ijms23169116>.
10. Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. *Cureus*. 2020;12(5):e8320. <https://doi.org/10.7759/cureus.8320>.
11. Villani A, Fabbrocini G, Ocampo-Candiani J, Ruggiero A, Ocampo-Garza SS. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. *J Eur Acad Dermatol Venereol*. 2021;35(7):1485-92. <https://doi.org/10.1111/jdv.17216>.
12. Sharma AN, Michelle L, Juhasz M, Muller Ramos P, Atanaskova Mesinkovska N. Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. *Int J Dermatol*. 2020;59(8):1013-9. <https://doi.org/10.1111/ijd.14933>.
13. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. *J Investig Dermatol Symp Proc*. 2005;10(3):184-9. <https://doi.org/10.1111/j.1087-0024.2005.10102.x>.
14. Dirección General de Epidemiología. Reporte de vigilancia genómica del virus SARS-CoV-2 en México. México: Gobierno de México; 2023 [Available from: <https://coronavirus.gob.mx/variantes-covid-19/>].
15. Aryanian Z, Balighi K, Hatami P, Afshar ZM, Mohandesi NA. The role of SARS-CoV-2 infection and its vaccines in various types of hair loss. *Dermatol Ther*. 2022;35(6):e15433. <https://doi.org/10.1111/dth.15433>.
16. Meisheri KD, Cipkus LA, Taylor CJ. Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K⁺ permeability. *J Pharmacol Exp Ther*. 1988;245(3):751-60.
17. Koç Yıldırım S, Erbağcı E, Demirel Öğüt N. Evaluation of patients with telogen effluvium during the pandemic: May the monocytes be responsible for post COVID-19 telogen effluvium? *J Cosmet Dermatol*. 2022;21(5):1809-15. <https://doi.org/10.1111/jocd.14883>.
18. Gentile P. Hair Loss and Telogen Effluvium Related to COVID-19: The Potential Implication of Adipose-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma as Regenerative Strategies. *Int J Mol Sci*. 2022;23(16). <https://doi.org/10.3390/ijms23169116>.
19. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. *Lancet Respir Med*. 2020;8(6):e46-e7. [https://doi.org/10.1016/S2213-2600\(20\)30216-2](https://doi.org/10.1016/S2213-2600(20)30216-2).
20. Hussain N, Agarwala P, Iqbal K, Omar HMS, Jangid G, Patel V, et al. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation. *J Med Virol*. 2022;94(4):1391-401. <https://doi.org/10.1002/jmv.27534>.
21. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. *J Am Acad Dermatol*. 2021;84(3):737-46. <https://doi.org/10.1016/j.jaad.2020.06.1009>.

22. Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. *F1000Res*. 2017;6:1650. <https://doi.org/10.12688/f1000research.11775.1>.
23. Bardelli A, Rebora A. Telogen effluvium and minoxidil. *J Am Acad Dermatol*. 1989;21(3 Pt 1):572-3. [https://doi.org/10.1016/s0190-9622\(89\)80231-2](https://doi.org/10.1016/s0190-9622(89)80231-2).
24. Trüeb RM, Caballero-Urbe N, Luu NC, Dmitriev A. Serious complication of low-dose oral minoxidil for hair loss. *JAAD Case Rep*. 2022;30:97-8. <https://doi.org/10.1016/j.jdc.2022.09.035>.

Figure 1. Hair-shedding scale through the visits. Changes in hair-shedding scale before and after oral minoxidil therapy.




Table 1. Baseline characteristics of patients with TE

| | |
|---------------------|-------------|
| Gender | |
| Female | 50 (72.5%) |
| Male | 19 (27.5%) |
| Age | 38.1 ± 11.7 |
| COVID-19 symptoms | |
| Mild/moderate | 55 (79.7%) |
| Severe | 8 (11.5%) |
| Asymptomatic | 6 (8.7%) |
| Vaccine status | |
| 1 shot | 52 (75.4%) |
| > 1 booster | 22 (31.9%) |
| Diagnosis | |
| Acute TE | 55 (79.7%) |
| Chronic TE | 14 (20.3%) |
| Previous diagnosis | |
| FPHL | 35 (50.7%) |
| MAGA | 17 (24.6%) |
| Lichen planopilaris | 1 (1.4%) |
| Healthy | 16 (23.2%) |
| Variant | |
| First wave | 16 (23.2) |
| Alpha | 4 (5.8) |
| Delta | 13 (18.8) |
| Omicron | 34 (49.3) |
| Unknown | 2 (2.9) |

COVID-19: Coronavirus disease 2019; FPHL: Female Patterned Hair Loss; MAGA: Male Androgenetic Alopecia; TE: Telogen effluvium.

Table 2. Characteristics of the CATE treatment with LDOM

| Hair-shedding scale | FPHL (n = 35) | MAGA (n = 17) | P-value* |
|--|---------------|---------------|----------|
| Change of 1 st visit vs 2 nd visit | 2 (2-1) | 1 (0-2) | .095 |
| Change 1 st visit vs 3 rd visit | 3 (3-4) | 3 (2-3) | .004 |
| Change of 1 st visit vs 4 th visit | 3 (3-4) | 3 (2.5-3) | .004 |
| <hr/> | | | |
| Initial dosage of minoxidil | | | |
| 1 mg | | 53 (76.8%) | |
| 2.5 mg | | 14 (20.3%) | |
| 5 mg | | 2 (2.9%) | |
| Final dosage of minoxidil | | | |
| 1 mg | | 48 (69.6%) | |
| 2.5 mg | | 6 (8.7%) | |
| 5 mg | | 15 (21.7%) | |
| Adverse effects | | | |
| Hypertrichosis | | 17 (24.6%) | |
| Edema of the limbs | | 4 (5.8%) | |
| Duration of therapy (days) | | 293 (217-394) | |
| Time elapsed between covid-19 and TE diagnosis (days) | | 117 (80-181) | |
| Time elapsed between TE diagnosis and 2 nd visit (days) | | 38 (33 – 54) | |
| Time elapsed between 2 nd visit and last visit (days) | | 93 (55 – 148) | |

CATE: Coronavirus disease 2019 associated telogen effluvium; LDOM: Low-dose of minoxidil; TE: Telogen effluvium.

Table 3. Median hair-shedding scale score at different visits.

| Hair-shedding scale | Median (IQR) |
|-----------------------|--------------|
| 1 st visit | 5 (5-6) |
| 2 nd visit | 4 (3-5) |
| 3 rd visit | 2 (2-3) |
| 4 th visit | 2 (1-2) |
| ¹ P-value* | <0.001 |
| ² P-value* | <0.001 |
| ³ P-value* | <0.001 |

IQR, interquartile range; ¹, 1st visit vs 2nd visit; ², 1st visit vs 3rd visit; ³, 1st visit vs 4th visit.

*Paired t-test.

Table 4. Comparison of hair-shedding scale score change between patients with FPHL and MAGA at different visits.

*Two sample t test.

Table 5. Hypertrichosis in those with a previous diagnosis of any type of alopecia, and according to the duration of treatment.

*Fisher's exact test; [§]Mann-Whitney U test.

| Hypertrichosis | Yes | No | P-value |
|------------------------------|---------------|---------------|--------------------|
| FAGA (n = 35) | 14 (40%) | 21 (60%) | 0.055* |
| MAGA (n = 17) | 2 (11.8%) | 15 (88.2%) | |
| Hypertrichosis | Yes (n = 17) | No (n = 52) | |
| Duration of treatment (days) | 396 (292-580) | 259 (204-363) | 0.004 [§] |